Categories
Analysis Forecast Market Size News

Hemophilia A Treatment Market Strong Development By Competitors, Global Analysis And Forecasts To 2026

Hemophilia A patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics. The increasing prevalent population of Hemophilia A and the rise in demand of the prophylactics treatments in developed markets will have a great impact on this market.

According to the US Centers for Disease Control and Prevention, hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B.  The number of people with hemophilia in the United States is estimated to be about 20,000 individuals. Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment.

Get sample copy of this report @ https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market/request-for-sample

As of January 2018, there are over 450 reported Clinical Trials for Hemophilia A with 50+ trials currently actively ongoing. Out of all the trials, 120+ studies are funded by the pharmaceutical companies alone. The major players with drugs in Phase III are Alnylam Pharmaceuticals, Sanofi (Genzyme), BioMarin Pharmaceutical, Hoffmann-La Roche, Sinocelltech Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Octapharma, LFB USA, Inc., Novo Nordisk A/S, Pfizer and others.

Polaris Market Research expects that with the expected launch of the promising treatments, the market is expected to expand in Hemophilia A segment. The United States dominates the Hemophilia A treatment market followed by Europe 5 and Japan. The prophylaxis segments are predicted to be the fastest growing segment whereas the on-demand therapy segment is expected to contribute close to ~50% to the market during the forecast period. With the increase in the R&D investments and rising drug innovations in this field, the market is expected to significantly expand in the next five years.

RNA based therapeutics and curative gene therapies are rapidly progressing through clinical development and are seen as an attractive segment of this market.

Market Size & Forecast of Hemophilia A Treatment(2016-2022)

  • Market Forecast by Disease Care
    • Prophylaxis-Market Forecast (2016-2022)
    • On-demand therapy-Market Forecast (2016-2022)
    • Inhibitor therapy- Market Forecast (2016-2022)
  • Market Forecast by G7 Countries (2016-2022)
    • United States- Market Forecast (2016-2022)
    • Germany- Market Forecast (2016-2022)
    • France-Market Forecast (2016-2022)
    • Italy- Market Forecast (2016-2022)
    • Spain- Market Forecast (2016-2022)
    • United Kingdom- Market Forecast (2016-2022)
    • Japan- Market Forecast (2016-2022)

Avail discount on this report @ https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world.

Contact us-

Mr. Likhil

Corporate Sales, USA

Polaris Market Research

Phone: 1-646-568-9980

Email: [email protected] 

Web: www.polarismarketresearch.com